Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 104Breast Neoplasms 76Fallopian Tube Neoplasms 47Multiple Myeloma 32Carcinoma, Ovarian Epithelial 27Neoplasms 23Lymphoma 16Sarcoma 13Triple Negative Breast Neoplasms 12Recurrence 12Neoplasm Metastasis 12Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 8Hodgkin Disease 8Neoplasms, Plasma Cell 6Prostatic Neoplasms 5Burkitt Lymphoma 5Solid Tumors 4Sarcoma, Kaposi 4Sarcoma, Ewing 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leiomyosarcoma 4Endometrial Neoplasms 4Carcinoma 4Breast Neoplasms, Male 4Uterine Cervical Neoplasms 3Rhabdomyosarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

tislelizumab 2Cystectomy 2vistusertib 1toripalimab 1olaparib 1liposomal doxorubicin 1durvalumab 1disitamab vedotin 1danvatirsen 1adavosertib 1Surgical Procedures, Operative 1Rutin 1Radiation 1RC48 antibody 1Neoadjuvant Therapy 1Gemcitabine 1Cisplatin 1Chemoradiotherapy 1AZD4547 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Cancer × liposomal doxorubicin × Clear all
NCT04101812 2019-09-26

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Tianjin Medical University Second Hospital

Phase 2 Unknown
60 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡